Arrowhead Pharmaceuticals CEO Christopher Anzalone sold 85,000 shares in the open market on Dec. 17, 2025, totaling approximately $5,443,462. This represented 2.17% of his direct holdings, leaving him with 3,831,957 shares. The sale was part of ongoing tax planning related to performance awards and aligns with previous transactions of similar scale. Arrowhead Pharmaceuticals focuses on RNAi therapeutics for liver disorders and other conditions, with recent FDA approval boosting stock prices. Investors should consider the company’s strong pipeline and future prospects before making investment decisions.

Read more at Nasdaq: Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million?